The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The SOHO Insider podcast with hosts Drs. Saad Usmani, Susan O'Brien, Andrew Kuykendall, and Megan Melody delivers fresh insights in the world of blood cancers right to you.
Dr. Usmani and Mina discuss the pivotal phase 3 MajesTEC-9 trial evaluating teclistamab monotherapy for patients with relapsed/refractory multiple myeloma who were previously exposed to lenalidomide and anti-CD38 antibodies.
In this SOHO Insider podcast, host Megan Melody, MD, from Tampa General Hospital, spoke with Nirav Shah, MD, professor at the Medical College of Wisconsin, on news from the 2026 […]
Gloria Iacoboni, MD, PhD, a hematologist at Vall d’Hebron University Hospital in Barcelona, Spain, spoke with Dr. James Day, a clinical research training fellow at UCL in London, during this SOHO Insider podcast episode recorded at the inaugural SOHO UK 2026 meeting.
John DiPersio, MD, PhD, current president of SOHO and director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine in St. Louis, Missouri, discusses the need for public-private partnerships to move novel therapies forward in the treatment of blood cancers. He also speaks about how cross-sector collaboration can create better research paths for the future.
In this podcast episode recorded at the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Megan Melody, MD, from Tampa General Hospital, spoke with Tycel J. Phillips, […]
In this episode of the SOHO Insider podcast, Douglas Tremblay discusses how to approach the treatment of essential thrombocythemia.
In this episode of the SOHO Insider podcast, Thomas Martin, MD, professor of medicine at University of California, San Francisco, talks with patient Craig Chase, an American father of two […]
SOHO Insider lymphoma podcast host Megan Melody, MD, assistant professor at the University of South Florida, interviews Tara Graff, MD, director of clinical trials and lymphoma specialist at Mission Cancer and Blood, part of University of Iowa Health Care, on treating patients with blood cancers in community settings, and whether the future belongs to bispecific antibodies or CAR-T therapies.
In this SOHO Insider podcast, Saad Usmani, MD, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, and Niels W C J van de Donk, MD, professor of hematology at Amsterdam UMC, discuss bispecific and trispecific antibodies, including early data from the trispecifics and the therapies moving into the frontline setting in multiple myeloma treatment.
In this episode of the SOHO Insider podcast, Susan O’Brien, MD, a professor of medicine from the Chao Family Comprehensive Cancer Center at the University of California, Irvine Medical Center, and Nitin Jain, MD, professor of medicine in the Department of Leukemia at the University of Texas MD Anderson Cancer Center, discuss updated results from the phase 3 FLAIR trial; the pair also speak about Bruton’s tyrosine kinase degraders in treating CLL.
